TSHA News and Press, Taysha Gene Therapies Inc.

2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...

2024-06-26 09:32:05 ET More on Taysha Gene Therapies Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky Taysha Gene Therapies stock slides after commence securities offering to raise $75 million Seeking Alpha’s Quant Rating on Taysha Gen...

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an ...

2024-06-26 05:58:14 ET More on related stocks: Rivian soars after new joint venture partner Volkswagen invests $5B Watch for more auto shockers after Rivian landed Volkswagen as a major partner FedEx rips 10% gain after earnings beat, favorable guidance FedEx...

2024-06-26 03:50:59 ET More on Taysha Gene Therapies Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky Taysha falls after data for Rett syndrome candidate Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset Seeking Alpha...

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commen...

2024-06-23 11:32:35 ET Summary Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trad...

2024-06-19 22:40:52 ET Summary Taysha Gene Therapies stock fell over 25% after disappointing data from Phase 1/2 REVEAL study of TSHA-102 in Rett Syndrome patients. TSHA-102 is a gene therapy targeting Rett Syndrome, a rare neurodevelopmental disorder with no approved disease-modi...

2024-06-18 09:30:05 ET More on Taysha Gene Therapies Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset Taysha...

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with differ...